FDA lifts hold on NeoRx' STR (Skeletal Targeted Radiotherapy) programme:
This article was originally published in Clinica
Executive Summary
The US FDA has lifted its hold on the further development of NeoRx' Skeletal Targeted Radiotherapy (STR) product for treating multiple myeloma, a cancer of the bone marrow. The agency's decision follows NeoRx's submission of data from a dosimetry study of STR, which had been requested by the FDA. The Seattle, Washington firm said that it intended to submit a phase III study protocol before the end of the second quarter of 2003 for review by the FDA. Three-year survival data on the STR phase I/II patients is expected to become available by the end of this year.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.